Standing on the Shoulders of Research: Multiple Myeloma Patient Advocacy
Gail
State: Virginia
Congressional District:
Diseases
Cancer
My Story
I was diagnosed with multiple myeloma 1.5 years ago. Had I been diagnosed more than ten years ago, the life expectancy for multiple myeloma patients was then 3 years or less. As a direct result of innovations developed through clinical trials and research, multiple myeloma patients are now living longer and with more treatment options. We now have greater opportunities to manage our care and symptoms. With continued funding of clinical trials, research, scientists and medical care, many multiple myeloma patients may have prospects for treatments that may delay disease progression and provide much improved quality of life during treatment. However, the work is not done.
I wish to advocate for continued funding for multiple myeloma clinical trials and research. We cannot afford to bypass the opportunity to build upon progress that has been made. Nor can we forgo the chance to further limit unnecessary suffering from negative health impacts and financial hardships from the cost of medical care. But, this cannot happen without continuing to invest in cutting-edge medical and scientific research.
I participated in a clinical trial for my first line of treatment therapy. My treatment in the clinical trial achieved the intended results within a shorter than expected treatment period, with limited impact upon my quality of life.
As a part of my treatment, I received a stem cell transplant, which I completed one year ago. I experienced complications that delayed my recovery and required careful navigation by my medical team. I have recovered substantially from those setbacks. I am doing well thanks to the comprehensive medical care that I received. I, like many other patients in remission, receive maintenance treatment for my condition. It is important that research continue to investigate therapies that lessen the impact on the patient, and provides alternatives when a treatment fails or the patient experiences a relapse of the cancer. We can only continue forward progress for patients like me and the multiple myeloma patients of the future by continuing investments in clinical trials and scientific research.
Many new therapies have been developed, tested and made available to patients over the last ten years. I am grateful that the building blocks of myeloma medical research and medical care reached new levels before my diagnosis. I advocate for those who would otherwise miss innovative treatments that may lessen medical or financial hardships or even save a life. Continued funding for multiple myeloma clinical trials, scientific research and medical treatments is crucial.
My Motivation and Inspiration
I am inspired by the many patients and caregivers that manage the challenging impacts of a rare disease, while seeking support and better outcomes for others.
Share This Story
Get the most from every Story
Find A Compelling Patient Story
Share it on social media.
Share Your Story On Our Network
Share your insights, challenges and what keeps you going.